Drug intelligence / Profile preview

68Ga-P137

Development stage: Unknown
Lead developer: Yunnan Baiyao
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
Administration: Intravenous

Overview

68Ga-P137 is a novel gallium-68 labeled radiopharmaceutical designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) in patients with prostate cancer. Unlike traditional PSMA-targeting agents that utilize a glutamate-urea (Glu-Urea) scaffold (such as 68Ga-PSMA-11 or 68Ga-PSMA-617), 68Ga-P137 features an oxalyldiaminopropionic acid-urea (ODAP-Urea) pharmacophore. This structural modification provides improved water solubility, lower urinary excretion, and faster clearance from non-target organs. In clinical studies, 68Ga-P137 demonstrates comparable diagnostic performance to 68Ga-PSMA-11 for detecting primary and metastatic prostate cancer lesions, while its reduced bladder accumulation and renal excretion potentially enhance the visualization of lesions near the urinary tract and reduce radiation exposure to the kidneys.

Other names: 68Ga-labeled ODAP-Urea-based PSMA ligandgallium (68Ga) P137gallium Ga 68 P137

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 68Ga-P137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-P137.